TL;DR
Together, these advancements represent a critical shift toward image-guided, dosimetry-driven radionuclide therapies that may work synergistically with existing immunotherapies to improve survival in metastatic melanoma.
The theranostic paradigm, combining molecular diagnosis and targeted radionuclide therapy in a single platform, has revolutionized precision oncology. Radiopharmaceutical theranostics enables targeted visualization, characterization, and treatment of malignancies through tumor-associated molecular targets, including pr...
Oncologic radionuclide theranostics integrates molecular imaging with targeted radionuclide therapy through target-specific ligands, allowing a shared molecular target to guide patient selection, lesion characterization, treatment delivery, dosimetry, and response monitoring. This review provides a cross-target compari...
Melanomas are the deadliest form of skin cancer owing to a lack of effective treatment options available for metastatic disease. Melanocortin 1 receptor (MC1R) is found overexpressed in the vast majority of melanomas, making this receptor a suitable target for a radiopharmaceutical to specifically deliver diagnostic an...
Findings support 161Tb as a next-generation theranostic radionuclide for RANKL-positive malignancies and provide a strong rationale for clinical translation, highlighting the value of repurposing a clinically established antibody for radiopharmaceutical therapy.
Prostate-specific membrane antigen (PSMA) is a Type II transmembrane glycoprotein markedly overexpressed on prostate cancer cells, enabling a single molecular target to support both positron emission tomography (PET) imaging and targeted radionuclide therapy. Over the past decade, PSMA-PET/CT has been incorporated into...
Radioligand therapy (RLT) has gained increasing prominence as an important therapeutic modality in oncology. By coupling a tumor-targeting ligand with a therapeutic radionuclide, therapeutic targeted RLT enables selective radiation delivery to a malignant site. Clinical validation of prostate-specific membrane antigen...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
